Insider · CIK 0001659625
Henry O Gosebruch
Files at ANIP (ANI PHARMACEUTICALS INC), NMRA (Neumora Therapeutics, Inc.), SLRN (ACELYRIN, Inc.). First filing -, latest -.
In brief
Henry O Gosebruch files SEC Form 4 as director, CEO and president at ANIP (ANI PHARMACEUTICALS INC), and also at NMRA (Neumora Therapeutics, Inc.), SLRN (ACELYRIN, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Henry O Gosebruch has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 12, 2025 | NMRA Neumora Therapeutics, Inc. | 15,000 0.01% of outstanding | $21k | Mar 12, 2025 | none |
| Feb 18, 2025 | NMRA Neumora Therapeutics, Inc. | 6,857 0.00% of outstanding | $11k | Feb 18, 2025 | none |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | ANIP ANI PHARMACEUTICALS INC | AGrant or award Common Stock | +6,662 | $0.00 | $0 | 6,662 | Aug 27, 2026 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Common Stock | -50,000 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Director Stock Option (right to buy)derivative | -92,158 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Director Stock Option (right to buy)derivative | -155,450 | - | - | 0 | May 23, 2025 |
| Jun 7, 2024 | SLRN ACELYRIN, Inc. | AGrant or award Director Stock Option (right to buy)derivative | +92,158 | $0.00 | $0 | 92,158 | Jun 11, 2024 |
| Feb 14, 2024 | NMRA Neumora Therapeutics, Inc. | AGrant or award Common Stock | +80,000 | $0.00 | $0 | 462,345 | Feb 16, 2024 |
| Feb 14, 2024 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +160,000 | $0.00 | $0 | 160,000 | Feb 16, 2024 |
Questions about Henry O Gosebruch
Answered from the filings on this page, as of the latest one.
Is Henry O Gosebruch buying or selling?
Henry O Gosebruch has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Henry O Gosebruch's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Henry O Gosebruch has 0.
Where does Henry O Gosebruch file Form 4?
Henry O Gosebruch has filed Form 4 at ANIP (ANI PHARMACEUTICALS INC); NMRA (Neumora Therapeutics, Inc.) as President & CEO; SLRN (ACELYRIN, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.